This session will explore how multidisciplinary advances have achieved exceptional cure rates in HL. Focusing on survivorship, the discussion will examine how contemporary treatments address late toxicities including secondary cancers, cardiovascular disease, and infertility through de-escalation and risk-adapted care strategies.
Prof Rajana Advani, the Saul Rosenberg Prof of Lymphoma at Standford Medicine, an internationally recognised expert in Hodgkin lymphoma who has led numerous clinical trials and contributed to global lymphoma treatment guidelines will be sharing more.
